Navigation Links
Abbott Presents Results of Clinical Studies Evaluating Its Investigational Treatment for Advanced Parkinson's Disease
Date:6/18/2012

DUBLIN, June 18, 2012 /PRNewswire/ -- Today Abbott (NYSE: ABT) announced results from five abstracts evaluating levodopa-carbidopa intestinal gel (LCIG), its investigational compound for advanced Parkinson's disease. The abstracts include the results from the second interim analysis of a long-term safety and tolerability trial, as well as secondary endpoint analyses from the Phase 3 pivotal trial. All of the abstracts were presented at The 16th International Congress of Parkinson's Disease and Movement Disorders, June 17-21 in Dublin, Ireland.

LCIG is currently approved in 40 countries. In the U.S., LCIG is an investigational therapy that is currently being evaluated in patients with advanced Parkinson's disease in additional Phase 3 clinical trials. In these trials, levodopa-carbidopa is administered in gel form, directly into the small intestine via a procedurally-implanted tube connected to a portable pump that delivers continuous supply of LCIG during awake hours.

Long-Term Safety and Tolerability
In a 54 week open-label safety and tolerability study of 354 patients with advanced Parkinson's disease, the primary endpoint of safety showed adverse events (AEs) were mostly mild to moderate, were generally associated with the Percutaneous Endoscopic Gastrostomy (PEG) tube placement procedure and its complications, were transient, and resolved over time.

In the secondary endpoint analysis from the open-label study, patients experienced an average daily "off" time of 6.7 hours, and 7.7 hours of "on" time without troublesome dyskinesia at baseline. "Off" time refers to periods of poor mobility, slowness and stiffness experienced by patients with Parkinson's disease, while "on" time refers to periods of good motor symptom control. At week 54, mean daily "off" time had decreased an average of 4.5 h
'/>"/>

SOURCE Abbott
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Grant & Eisenhofer Represents Lead Whistleblower in Historic $1.6 Billion Settlement with Abbott Laboratories Over Off-Label Marketing of Antiepileptic Medication Depakote
2. Abbott Announces Collaboration with Syngene to Open First Nutrition R&D Center in India
3. Frost & Sullivan: Developing Integration Capabilities Presents a Real Opportunity for Vendors in the European CIS Market
4. This Week: UBM Canon Presents an Online Event and Conference Dedicated to Emerging Trends in Medical Device Outsourcing/Contract Manufacturing
5. Berg Pharma presents at ASCO, poised to lead field in cancer metabolism with Phase II trials of BPM 31510
6. Lexicon Presents Data Regarding the Mechanism of Action and Safety of LX4211 at American Diabetes Association Meeting
7. Vanda Pharmaceuticals Inc. Presents Scientific Posters at Society for Research on Biological Rhythms (SRBR) Annual Meeting
8. Boehringer Ingelheim Presents First Data for Tiotropium in Adolescents with Moderate Persistent Asthma
9. Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
10. Boston Scientific Endoscopy Presents Promising Clinical Data During Digestive Disease Week ®
11. Sanofi Pasteur Presents Pediatric Data on Investigational Quadrivalent Influenza Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... 2014 Arbor Pharmaceuticals, LLC. - Product ... Markets Direct,s, ,Arbor Pharmaceuticals, LLC. - Product Pipeline ... Arbor Pharmaceuticals, LLC.,s pharmaceutical research and development focus. ... current therapeutic developmental pipeline of Arbor Pharmaceuticals, LLC.,s, ... assessment by drug target, mechanism of action (MoA), ...
(Date:9/30/2014)... Sept. 30, 2014  According to their CEO, ... cancer clinical trials is going through a complete ... the work of the current clinical trial management ... ,next generation, clinical trials, which will ultimately drive ... The company has been recognized by the ...
(Date:9/30/2014)... A study using a relatively new imaging ... at the composition of carotid artery disease and has ... the disease, a leading cause of stroke. ... September 2010 and May 2012, was featured in the ... American College of Cardiology (JACC) Cardiovascular Interventions. Interventional ...
Breaking Medicine Technology:Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 2Arbor Pharmaceuticals, LLC. - Product Pipeline Review - 2014 3Small Denver Company Pharmatech driving a large revolution in how cancer clinical trials are managed 2New Imaging Tool May Allow Tailoring of Stroke Prevention to Each Patient 2
... HAYWARD, Calif., Oct. 26 Anthera Pharmaceuticals, Inc. (Nasdaq: ... to treat serious diseases associated with inflammation, today announced ... after market close on Tuesday, November 2, 2010.  Anthera ... Time in conjunction with the release.Conference Call Access:Date: , ...
... Oct. 26 Lexicon Pharmaceuticals, Inc. (Nasdaq: ... discovering breakthrough treatments for human disease, announced today that ... on Friday, November 5, 2010 before the financial markets ... discuss its clinical development progress and financial results for ...
Cached Medicine Technology:Anthera Announces Third Quarter 2010 Financial Report and Conference Call 2Lexicon to Provide Clinical Pipeline Update and Report Third Quarter 2010 Financial Results 2
(Date:9/30/2014)... 2014 Integrated Medicine Alliance , ... another new medical specialty practice through a unique partnership ... will be located within the company’s Shrewsbury location and ... Isaac Tawfik of American Heart Center, P.C., a highly ... will offer Integrated Medicine Alliance patients top notch cardiovascular ...
(Date:9/30/2014)... University of Maryland-led research team has been awarded ... Institutes of Health (NIH) to develop new imaging ... our understanding of how large networks of neurons ... This knowledge will help researchers identify the precise ... behavior, like decision-making and speaking, and alterations in ...
(Date:9/30/2014)... Vegas, NV (PRWEB) September 30, 2014 ... is helping people perform better in and out of the ... and memory has caught the attention of Shane Michaels, prompting ... day-to-day grind, fatigue is the reason most people simply just ... whether that means staying focused at work, getting the motivation ...
(Date:9/30/2014)... 2014 Hospice & Palliative Care ... Celebration” gala, honoring three outstanding individuals for their ... to provide extraordinary and dignified comfort, care and ... or life-limiting illness. , The event was held ... and recognized William (Bill) J. McGuinness, Director of ...
(Date:9/30/2014)... SHELBY TOWNSHIP, Mich. (PRWEB) September 30, 2014 ... inventive chronic knee pain program of care ... patients. , His clinic—Johnson Chiropractic Neurology & ... focusing on the knee. It also addresses sources of ... as well as the “neurokinetic chain” from the brain ...
Breaking Medicine News(10 mins):Health News:Integrated Medicine Alliance Announces New Cardiology Practice 2Health News:UMD receives inaugural BRAIN Initiative Award 2Health News:Elevate: Review Exposes Blue Star Nutraceutical’s Latest Supplement for Ultimate Brain Function, Focus, and Energy 2Health News:Hospice & Palliative Care of Westchester Honors Outstanding Individuals at Annual ‘In Celebration’ Gala 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 2Health News:Newly Developed Program Eases Chronic Knee Pain without Surgery and in as Little as Two Days 3
... March 17 /PRNewswire/ - Organogenesis, Inc., announced,today ... has joined the company as,vice president of ... Dr. Bates combines more than twelve ... industry experience. He has practiced in,orthopedic, dermatologic, ...
... The neighborhoods people live in can help inspire ... physically active, new research suggests. , Residents of neighborhoods ... female-headed families are less likely than others to exercise, ... poorer people are less likely to exercise, researchers say. ...
... the 2008 Presidential election campaign so now is a critical ... the future and the challenges our society will face as ... professor of Health Law, Bioethics, and Human Rights at BUSPH ... These challenges include integrating the new genetics into care, improving ...
... Blood Testing Requirements, VANCOUVER, March 17 /PRNewswire-FirstCall/ ... that the U.S. Food and Drug Administration (FDA),has ... supplement (sNDA) for,Aczone(TM) and has removed the glucose-6-phosphate ... are extremely pleased to report the FDA decision ...
... the Need Is Still There, WASHINGTON, March 17 ... still suffering emotionally from the,effects of the storms will ... Red Cross Hurricane Recovery Program (HRP) has,announced it will ... May 31, 2008. The Red Cross Emotional Support Program,allows ...
... 17 Hologic, Inc.,(Nasdaq: HOLX ) today announced ... Officer, will be presenting at the Lehman,Brothers Eleventh Annual ... Miami Beach Hotel in Miami, Florida., Interested parties ... of,Hologic,s investor presentation on Thursday, March 20, at 10:15 ...
Cached Medicine News:Health News:Organogenesis Names Regenerative Medicine Expert Dr. Damien Bates Vice President, Medical Affairs 2Health News:Organogenesis Names Regenerative Medicine Expert Dr. Damien Bates Vice President, Medical Affairs 3Health News:Neighborhoods play key role in how much people exercise, study says 2Health News:Neighborhoods play key role in how much people exercise, study says 3Health News:BU's School of Law, Public Health to hold conference on the future of health law 2Health News:QLT announces positive FDA action on Aczone(TM) 2Health News:QLT announces positive FDA action on Aczone(TM) 3Health News:Red Cross Announces an Extension for Emotional Support Assistance for 2005 Hurricane Survivors 2Health News:Hologic to Present at Lehman Brothers Healthcare Conference 2
... 5mm AEM Laparoscopic Instruments incorporate a layered ... are shielded and monitored to prevent stray ... instrument caused by insulation failure or capacitive ... protective shield built into all AEM Instruments ...
... The 5mm AEM Laparoscopic Instruments incorporate ... AEM Instruments are shielded and monitored to ... of the instrument caused by insulation failure ... risk. The protective shield built into all ...
SOLOS Endoscopy shares your commitment to provide every patient with the highest quality care available through our ongoing research and development of advanced surgical instruments and diagnostic so...
... Enhanced features including aspiration holes ... in laparoscopic procedures requiring precise dissection ... and increased suction demands. ,Flexible ... retractable and nonretractable electrodes and multiple ...
Medicine Products: